overt diabetes
Overview
Overt diabetes refers to clinically manifest diabetes mellitus, typically distinguished from milder dysglycemia or gestational hyperglycemia by meeting diagnostic thresholds for diabetes at the time of detection. In obstetric and endocrine contexts, the term is often used to describe diabetes that is already present or clearly established early in pregnancy, rather than hyperglycemia first recognized later in gestation. As a disease state, overt diabetes is associated with chronic hyperglycemia, insulin deficiency and/or insulin resistance, and a broad range of microvascular and macrovascular complications.
Biologically, overt diabetes is relevant because sustained elevation of blood glucose affects multiple organ systems, including the retina, kidney, heart, skeletal muscle, nervous system, and skin. It also influences infection risk, wound healing, and pregnancy outcomes. Recent research contexts linked to overt diabetes emphasize its role as a clinically important target for early detection, complication prevention, and risk stratification.
Recent Publications Summary
Recent publications have examined overt diabetes in a range of clinical and epidemiologic settings, most often as a comorbid condition or risk factor rather than as the primary intervention target. In patients with moderate-to-severe coronary artery calcification undergoing first percutaneous coronary intervention, diabetes mellitus was one of several cardiovascular-kidney-metabolic risk factors evaluated for sex-specific prognostic significance, alongside chronic kidney disease, obesity, hypertension, and hypertriglyceridemia 42462211Jul. In a prospective cohort of patients receiving peritoneal dialysis, diabetes mellitus was compared with impaired fasting glucose and normal fasting glucose, with the study focusing on mortality and major adverse cardiovascular events as well as measures of β-cell function and insulin resistance 42402705Jul. Another cohort study in hypertensive UK Biobank participants defined cardiometabolic multimorbidity as the occurrence of at least two of type 2 diabetes, ischemic heart disease, and stroke when assessing physical activity patterns and incident cardiometabolic outcomes 42396800Jul.
Several studies addressed diabetes care, access, and socioeconomic patterning. In Japan, self-reported current diabetes care use increased steadily from 1986 to 2022, with widening sex inequalities and educational differences, particularly among working-age adults 42457244Jul. In the United States, analyses of NHANES and All of Us data found that higher educational attainment and income were associated with lower prevalence of type 2 diabetes and obesity, while the strength of these associations varied across racial and ethnic subgroups 42418390Jul. A prospective longitudinal cohort of U.S. Veterans also examined incident diabetes after SARS-CoV-2 infection, although the abstract provided does not report the results 42361118Jun.
Other publications focused on diabetes management, technology, and adjunctive interventions. A randomized controlled trial evaluated an educational app for complementary therapy in diabetes management, with outcomes including health literacy, quality of life, and diabetes empowerment 42361247Jun. Real-world reports on diabetes technology described usage trends across the lifespan and across European countries, emphasizing continuous glucose monitoring, automated insulin delivery, smart insulin pens, and related technologies in people with type 1 or type 2 diabetes 42100882May41933491Apr. In elderly people with type 2 diabetes without osteoporosis, a randomized clinical trial assessed exercise training and its effects on non-invasive measures of bone health 42103115May. A subanalysis of the EARNEST-PVI trial reported that concomitant diabetes mellitus diminished the efficacy of left atrial additional ablation following pulmonary vein isolation in persistent atrial fibrillation 41656093Feb.
What Changes, What Holds
1. diabetes is being used as a prognostic comorbidity across cardiovascular and kidney disease settings, not as a new defining feature of overt diabetes
NEW DIRECTION These studies extend the clinical reach of overt diabetes into risk stratification, showing it as one factor among several in coronary calcification, dialysis, and cardiometabolic multimorbidity analyses 42462211Jul42402705Jul. That adds context for prognosis and interaction with other metabolic disease, but it does not alter the baseline account of overt diabetes as clinically manifest diabetes with systemic complications.
2. Social and access gradients now appear central to how overt diabetes is detected and managed
NEW DIRECTION The new work suggests that care use, education, income, sex, and race or ethnicity shape who receives diabetes care and who carries type 2 diabetes or obesity, broadening the baseline beyond biology to include health-system and socioeconomic patterning 42457244Jul42418390Jul. A separate cohort on post-SARS-CoV-2 incident diabetes is too incomplete in the summary to change the account, but it reinforces that diabetes surveillance is expanding into new epidemiologic contexts 42361118Jun.
3. Management is increasingly defined by digital tools and adjunctive support rather than glucose thresholds alone
METHOD The app trial and technology reports mainly change how diabetes is managed and measured, emphasizing education, empowerment, continuous glucose monitoring, automated insulin delivery, and smart pens 42361247Jun42100882May. The exercise and ablation findings add treatment-context effects, but they do not revise what overt diabetes is; they show how comorbidity can modify response to interventions in older adults and atrial fibrillation care 42103115May41656093Feb.
Overview update candidates: diabetes care access and socioeconomic patterning; expanding use of diabetes technology and adjunctive management tools.
overt diabetes
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding overt diabetes are described as follows:
- diabetic foot ulcer (Disease) — 5 papers: PMIDs 42399485, 42368316, 42325033, 42296174, etc.
- hyperinsulinemic T2D patients (Disease) — 4 papers: PMIDs 42332399, 42324965, 42269219, 42035619
- obesity (Disease) — 4 papers: PMIDs 42461970, 42445960, 42429693, 42105573
- uncomplicated hypertension (Disease) — 4 papers: PMIDs 42423642, 42361024, 42207966, 42159541
- Cancers (Clinical Metric) — 3 papers: PMIDs 42361024, 42105573, 41894851
- cardiovascular disease (Disease) — 3 papers: PMIDs 42424628, 42269129, 42207966
- chronic renal insufficiency (Disease) — 3 papers: PMIDs 42419892, 42334402, 42114520
- diabetic nephropathy (Disease) — 3 papers: PMIDs 42286730, 42169531, 42030650
- insulin resistance (Biological Process) — 3 papers: PMIDs 42440372, 42097306, 41805838
- Automated Insulin Delivery (Therapy) — 2 papers: PMIDs 42091117, 41858085
- glycemic control (Clinical Metric) — 2 papers: PMIDs 42461834, 42440372
- hemodialysis (Therapy) — 2 papers: PMIDs 42402705, 42224118
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study overt diabetes:
- streptozotocin (STZ) (Chemical) — 10 papers: PMIDs 42446804, 42430106, 42340852, 42324965, etc.
- brain–computer interface (Technology) — 5 papers: PMIDs 42461449, 42457308, 42440210, 42429693, etc.
- high-fat diet (Other) — 5 papers: PMIDs 42365576, 42340852, 42324965, 42269219, etc.
- Aged garlic extract (Therapy) — 4 papers: PMIDs 42457308, 42424368, 42333704, 41645741
- robot assisted thoracic surgery (Organism) — 4 papers: PMIDs 42289507, 42237712, 42178013, 42170982
- AI/machine learning (Technology) — 3 papers: PMIDs 42462211, 42406913, 42399485
- continuous glucose monitor (Technology) — 3 papers: PMIDs 42224118, 41933491, 41858085
- Leprdb/J (db/db) mice (Organism) — 3 papers: PMIDs 42365576, 42176503, 42035619
- multivariable logistic regression (Technology) — 3 papers: PMIDs 42461970, 42461449, 42419892
- uncomplicated hypertension (Disease) — 3 papers: PMIDs 42461970, 42461449, 42424368
- aged diabetic rat model (Organism) — 2 papers: PMIDs 42318610, 42229217
- copper(2+) (Chemical) — 2 papers: PMIDs 42406729, 42318610
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to overt diabetes include:
- semaglutide (Therapy) — 5 papers: PMIDs 42457308, 42207966, 42114520, 42108418, etc.
- uncomplicated hypertension (Disease) — 3 papers: PMIDs 42462211, 42457244, 42269125
- blood glucose (Clinical Metric) — 2 papers: PMIDs 42341058, 42325033
- chronic renal insufficiency (Disease) — 2 papers: PMIDs 42462211, 42461834
- diabetic retinopathy (Disease) — 2 papers: PMIDs 42308470, 41645537
- obesity (Disease) — 2 papers: PMIDs 42462211, 42418390
- PRKAA1 (Protein) — 2 papers: PMIDs 42424320, 41990533
- Sirt1/Nrf2/GPX4 signaling pathway (Pathway) — 2 papers: PMIDs 42424320, 42090904
- tirzepatide (Therapy) — 2 papers: PMIDs 42207966, 42114520
- WPI and CUR (Other) — 2 papers: PMIDs 42418583, 42233718
- 23-valent pneumococcal polysaccharide vaccine (Therapy) — 1 paper: PMIDs 42334402
- 5-methoxytryptamine (Other) — 1 paper: PMIDs 42365576
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with overt diabetes include:
- blood glucose (Clinical Metric) — 6 papers: PMIDs 42406729, 42333022, 42324965, 42237712, etc.
- oxidative stress (Biological Process) — 6 papers: PMIDs 42446804, 42437006, 42430106, 42324965, etc.
- proinflammatory cytokine (Biological Process) — 6 papers: PMIDs 42333704, 42324965, 42269219, 42105573, etc.
- hazard ratio (Clinical Metric) — 4 papers: PMIDs 42462211, 42396805, 42396800, 42153665
- insulin resistance (Biological Process) — 4 papers: PMIDs 42402705, 42365576, 42340852, 42113684
- MDA content (Clinical Metric) — 4 papers: PMIDs 42324965, 42269219, 42224419, 42178013
- Nrf-2-SLC7A11-GSH pathway (Pathway) — 4 papers: PMIDs 42300970, 42269219, 42224419, 42178013
- uncomplicated hypertension (Disease) — 4 papers: PMIDs 42440210, 42433002, 42430313, 42429693
- catalase (Protein) — 3 papers: PMIDs 42269219, 42224419, 42178013
- hemoglobin A1c (Clinical Metric) — 3 papers: PMIDs 42442740, 42440210, 42259339
- insulin (Protein) — 3 papers: PMIDs 42418583, 42340852, 42105573
- large language model parameter (Clinical Metric) — 3 papers: PMIDs 42324965, 42105573, 41967780
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding overt diabetes are summarized below:
- clinical care (Other) — 2 papers: PMIDs 42442740, 41933491
- Sextans (Other) — 2 papers: PMIDs 42461970, 42440372
- therapeutic reversal (Therapy) — 2 papers: PMIDs 42424320, 42035619
- wound healing (Clinical Metric) — 2 papers: PMIDs 42300970, 42236253
- adjusted mortality (Other) — 1 paper: PMIDs 42433002
- age-related functional status (Other) — 1 paper: PMIDs 42269125
- age-stratified screening and prevention strategies (Other) — 1 paper: PMIDs 42461449
- Aged garlic extract (Therapy) — 1 paper: PMIDs 42461970
- AMPK ADaM site (Other) — 1 paper: PMIDs 41967351
- amyloidogenic pathways (Biological Process) — 1 paper: PMIDs 42178013
- anti-inflammatory agent (Other) — 1 paper: PMIDs 42318610
- antibacterial and bactericidal activity (Biological Process) — 1 paper: PMIDs 42318610